Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned a consensus rating of “Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $46.43.

Several brokerages recently issued reports on DNTH. Wedbush dropped their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Raymond James increased their price target on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Finally, Oppenheimer upped their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. Quest Partners LLC boosted its stake in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after acquiring an additional 1,124 shares in the last quarter. Fred Alger Management LLC boosted its position in Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics in the second quarter valued at $112,000. MetLife Investment Management LLC increased its position in shares of Dianthus Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after buying an additional 7,854 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after buying an additional 8,473 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Trading Up 0.7 %

DNTH stock opened at $23.99 on Monday. The company has a market capitalization of $710.10 million, a P/E ratio of -9.60 and a beta of 1.84. The business has a 50 day simple moving average of $26.66 and a 200-day simple moving average of $26.54. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.